TITLE

Drotrecogin Alfa (Activated)

AUTHOR(S)
Lyseng-Williamson, K.A.; Perry, C.M.
PUB. DATE
February 2002
SOURCE
Drugs;2002, Vol. 62 Issue 4, p617
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
▴ Drotrecogin alfa (activated), recombinant human activated protein C, inhibits coagulation and inflammation and promotes fibrinolysis in patients with severe sepsis. ▴ 850 patients with severe sepsis treated with intravenous drotrecogin alfa (activated) 24 μg/kg/h for 96 hours had a significantly greater reduction in 28-day all-cause mortality (24.7%) than 840 placebo recipients (30.8%) in a randomised, double-blind, placebo-controlled study. The drug was associated with a 19.4% reduction in the relative risk of death at 28 days compared with placebo. ▴ Baseline characteristics of and pre-existing conditions in patients with sepsis appeared to have no effect on the efficacy of drotrecogin alfa (activated). ▴ A significantly greater reduction in median percentage change from baseline plasma D-dimer levels (a coagulation marker) was seen with drotrecogin alfa (activated) treatment than with placebo on study days 1 to 7 in patients with severe sepsis. On study days 1, 4, 5, 6 and 7, a significantly greater median reduction in interleukin-6 levels (an inflammation marker) from baseline was seen with drotrecogin alfa (activated) treatment than placebo. ▴ Drotrecogin alfa (activated) was associated with an increased incidence of serious bleeding events during the infusion period [2.4% vs 1.0% with placebo; p = 0.024] and the 28-day study period (3.5 vs 2.0%; p = 0.06) of the efficacy trial. This increase was primarily related to procedure-related events; there were no significant differences between the treatment groups in nonprocedure-related serious bleeding events. The most frequent site of bleeding was the gastrointestinal tract. ▴ With the exception of bleeding events, there were no clinically significant differences between treatment groups in the efficacy trial in the incidence of adverse events. ▴ Of the 210 deaths in patients with severe sepsis treated with drotrecogin alfa (activated) 24 μg/kg/h in the efficacy trial, four deaths due to haemorrhage and one due to cerebral oedema were possibly related to the study drug.
ACCESSION #
6280834

 

Related Articles

  • Gulf casualties to receive trial drug. Coghlan, Andy // New Scientist;2/23/91, Vol. 129 Issue 1757, p18 

    Reports on the results of clinical trials of the drug Centoxin, which combats severe blood poisoning or septicemia. U.S. Food and Drug Administration's (FDA) consideration of the drug valuable in the treatment of battlefield injuries; Stipulation that doctors in the Persian Gulf cannot...

  • Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. Stefanie Swoboda; Michael Ober; Christian Hainer; Christoph Lichtenstern; Christoph Seiler; Constanze Wendt; Torsten Hoppe-Tichy; Markus Büchler; Markus A. Weigand // Journal of Antimicrobial Chemotherapy (JAC);Mar2008, Vol. 61 Issue 3, p729 

    : Objectives Adequate antimicrobial therapy is crucial for the survival of critically ill patients with severe nosocomial infections. Tigecycline, the first available agent in the new class of glycylcyclines, is active against multiresistant Gram-positive and Gram-negative bacteria. The aim of...

  • My paper 20 years later: effects of dobutamine on the VO/DO relationship. Vincent, Jean-Louis; De Backer, Daniel // Intensive Care Medicine;Nov2014, Vol. 40 Issue 11, p1643 

    Introduction: Oxygen uptake (VO) is independent of oxygen delivery (DO) over a wide range of values, because O extraction can readily adapt to changes in DO. However, VO can become DO-dependent in acute circulatory failure. Methods: Various methods of evaluating the presence of VO/DO dependency...

  • Early initiation of drotrecogin alfa worthwhile in severe sepsis.  // PharmacoEconomics & Outcomes News;3/24/2007, Issue 524, p11 

    The article discusses research being done on the clinical use of drotercogin alfa in patients with severe sepsis in the U.S. It references a study by F. R. Ernst and colleagues, published in the January 2007 issue of "Current Medical research and Opinion." The researchers examined hospital...

  • Sepsiste Steroid Kullanımı. Kuşkonmaz, Şerife Mehlika; Tütüncü, Neslihan Başcıl // Turkish Journal of Endocrinology & Metabolism;Dec2013, Vol. 17 Issue 4, p121 

    Sepsis is defined as "systemic signs and symptoms of infection in the presence of infection". Nearly one fourth of sepsis cases eventually die. Therefore, rapid and correct management of sepsis is important. There is no reliable test to evaluate adrenal insufficiency in sepsis due to the changes...

  • CD28 Homodimer Interface Mimetic Peptide Acts as a Preventive and Therapeutic Agent in Models of Severe Bacterial Sepsis and Gram-Negative Bacterial Peritonitis. Ramachandran, Girish; Kaempfer, Raymond; Chung, Chun-Shiang; Shirvan, Anat; Chahin, Abdullah B.; Palardy, John E.; Parejo, Nicolas A.; Chen, Yaping; Whitford, Melissa; Arad, Gila; Hillman, Dalia; Shemesh, Ronen; Blackwelder, William; Ayala, Alfred; Cross, Alan S.; Opal, Steven M. // Journal of Infectious Diseases;Mar2015, Vol. 211 Issue 6, p995 

    Background. Severe gram-negative bacterial infections and sepsis are major causes of morbidity and mortality. Dysregulated, excessive proinflammatory cytokine expression contributes to the pathogenesis of sepsis. A CD28 mimetic peptide (AB103; previously known as p2TA) that attenuates CD28...

  • Trials `a must' for disputed cholesterol drugs. Vines, G. // New Scientist;2/22/92, Vol. 133 Issue 1809, p11 

    Reports on the dispute in Great Britain over cholesterol-lowering drugs. The need for large trials of a new generation of these drugs, known as statins; The two sides of the dispute; Press reports that have led to fears of a consumer backlash against the drugs.

  • The limited precision of phase I trials. Christian, Michaele C.; Korn, Edward L. // JNCI: Journal of the National Cancer Institute;11/16/94, Vol. 86 Issue 22, p1662 

    Editorial. Criticizes conventional phase I trial designs' tendency to give inappropriate dose recommendations. National Cancer Institute (NCI) Cancer Therapy Evaluation Program's commitment to exploring alternative phase I trial designs; Strategies for improving precision of estimating the...

  • Toxicity tests minus animals? Gillis, Anna Maria // BioScience;Mar1993, Vol. 43 Issue 3, p137 

    Reports that cellular and tissue techniques are in, but as long as public safety is at stake, animals will continue to be used in testing. The work of toxicology; In vitro models; Human skin modeling; What tests can determine; Characteristics of a proper model; Validation.

  • Precocious puberty.  // Discover;Jul92, Vol. 13 Issue 7, p13 

    Studies the medical condition known as precocious puberty. Symptoms; New drug, called histrelin acetate, that shows promise in treating precocious puberty, particularly in girls; High cost of the drug; Future prospects.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics